Balance Wealth
BMRN icon

Balance Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Balance Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$448 Buy
+7
New +$441 ﹤0.01% 901

Other funds holding BMRN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Balance Wealth's BMRN Position: Q3 2026 in Review

Balance Wealth opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2026: 7 shares worth $448. The stake represents ﹤0.01% of the portfolio and ranks #901 among its holdings.

430 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Balance Wealth held 7 shares of BioMarin Pharmaceuticals worth $448 as of Q3 2026.
  • BioMarin Pharmaceuticals was a new Balance Wealth position in Q3 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Balance Wealth's portfolio in Q3 2026, its #901 holding.
  • 430 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Balance Wealth's 13F filing for Q3 2026, filed 27 Oct 2026.